What happened, in summary

Steven Huff was 29, newly engaged, and starting a teaching career when shortness of breath, a daily cough, and a lump near his collarbone led to a lung cancer diagnosis. Doctors told him he had Stage IV non-small cell lung adenocarcinoma, with cancer in both lungs and other sites including the liver, spine, sacrum, chest lymph nodes, and a neck/collarbone lymph node. At first, chemotherapy seemed likely enough that he had a port placed. An immunotherapy-combination trial was also discussed before biomarker results were final. A second-opinion doctor suspected his cancer might be ALK-positive, and testing confirmed an ALK alteration. That changed the course of treatment. Instead of starting chemotherapy, Steven began an oral targeted therapy, a TKI taken twice daily, on June 22. The specific drug name was not stated. Because the disease was Stage IV, surgery was not an option at diagnosis; the goal became controlling the cancer as a chronic illness. Steven also banked sperm before treatment, which later helped him and his wife, Emily, move forward with family planning. The targeted therapy worked well enough that he returned to teaching within weeks and continued regular scans and liver monitoring. As of September 2025, Steven was living with Stage IV ALK-positive lung cancer, doing well on treatment, and building a family life around hope rather than fear.